Advertisement

Topics

STAT Plus: Gilead faces a hepatitis C patent challenge in China by Doctors Without Borders

13:04 EST 18 Dec 2017 | STAT

The move comes after Gilead said it would charge $8,900, or $100 a pill, in China for Sovaldi, one of two components in Epclusa.

Original Article: STAT Plus: Gilead faces a hepatitis C patent challenge in China by Doctors Without Borders

NEXT ARTICLE

More From BioPortfolio on "STAT Plus: Gilead faces a hepatitis C patent challenge in China by Doctors Without Borders"

Advertisement
Quick Search
Advertisement
Advertisement